June 2024
1. JIANG R, Feng Y, Chen Y, Cheng X, et al
   Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial.
   Nat Med. 2024 Jun 1. doi: 10.1038/s41591-024-02981.
   

   >> Share

   
   May 2024
2. WU X, Liu J, Wang J, Wang L, et al
   Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial.
   Nat Med. 2024 May 15. doi: 10.1038/s41591-024-03003.
   

   >> Share

   
   
3. FRIEDMAN CF, Manning-Geist BL, Zhou Q, Soumerai T, et al
   Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.
   Nat Med. 2024;30:1330-1338.
   

   >> Share

   
   January 2024
4. AMGAD M, Hodge JM, Elsebaie MAT, Bodelon C, et al
   A population-level digital histologic biomarker for enhanced prognosis of invasive breast cancer.
   Nat Med. 2024;30:85-97.
   

   >> Share

   
   June 2023
5. YAP TA, Fontana E, Lee EK, Spigel DR, et al
   Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.
   Nat Med. 2023;29:1400-1411.
   

   >> Share

   
   February 2023
6. O'LEARY K
   A biomarker-driven therapy for ovarian cancer.
   Nat Med. 2023 Feb 16. doi: 10.1038/d41591-023-00018.
   

   >> Share

   
   August 2020
7. GRZYMSKI JJ, Elhanan G, Morales Rosado JA, Smith E, et al
   Population genetic screening efficiently identifies carriers of autosomal dominant diseases.
   Nat Med. 2020;26:1235-1239.
   

   >> Share

   
   
8. BRASTIANOS PK, Lee EQ, Cohen JV, Tolaney SM, et al
   Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.
   Nat Med. 2020;26:1280-1284.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share